Jump to Main Content

Annual Meeting Press

Annual Meeting Press Program

ASH is pleased to offer credentialed media the following 60-minute press briefings. This year, there will be one virtual briefing before the meeting and several on-site press briefings that will also be livestreamed on the annual meeting virtual platform. All briefings will include thematic overviews, brief presentations by each of the press presenters, and live Q&A. Please note carefully the embargo times indicated below. All times listed reflect the Central time zone.

Virtual-only briefing

Building Solutions to Challenges in Health Equity 

Moderator: Chancellor Donald, MD
Briefing time: Wednesday, Dec. 7, 2022: 1:00 p.m. – 2:00 p.m.
Embargo lift time: Saturday, Dec. 10, 2022: 7:00 a.m.

  • 140: Social Determinants of Health and Pulmonary Embolism Treatment and Mortality: The Nationwide Inpatient Sample – presenter Mary Cushman, MD
  • 850: Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis – presenter Matthew Maurer, MD
  • 127: Analysis of 372 Adult Allograft Recipients Reveals Associations between Non-European Ancestry, Low Socioeconomic Status, and Receipt of HLA-Disparate Grafts – presenter Warren Fingrut, MD
  • 3638: An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia – presenter Molly Tokaz, MD

On-site and virtual briefings

Treating Blood Cancers: Changing the Status Quo 

Moderator: Mikkael A. Sekeres, MD, MS
Briefing time: Saturday, Dec. 10, 2022: 8:30 a.m. – 9:30 a.m.
Embargo lift time: Saturday, Dec. 10, 2022: 8:30 a.m.

  • 214: High Dose Methotrexate Does Not Reduce the Risk of CNS Relapse in Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma. Results of the Randomised Phase III Study UKALL 2011 – presenter Amy Kirkwood, MSc
  • 4: In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial – presenter Johannes Schetelig, MD, MSc
  • 169: Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial – presenter Federico Stella, MD
  • 1: Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network – presenter Martin Dreyling, MD

New Drugs, New Targets

Moderator: Stephanie Lee, MD
Briefing time: Saturday, Dec. 10, 2022: 10:30 a.m. – 11:30 a.m.
Embargo lift time: Saturday, Dec. 10, 2022: 10:30 a.m.

  • 3: Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV) – presenter Catherine Broome, MD
  • 157: Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1 – presenter Ajai Chari, MD
  • 581: Gene Therapy Equity in Sickle Cell Disease: Distributional Cost-Effectiveness Analysis (DCEA) of Gene Therapy Vs. Standard-of-Care in Patients with Sickle Cell Disease in the United States – presenter George Goshua, MD, MSc
  • Combined presentation:
    • 2348: Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials – presenter Franco Locatelli, MD
    • 3665: Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia – presenter Franco Locatelli, MD

No Minor Matter: Optimizing Pediatric Care

Moderator: Catherine Bollard, MD
Briefing time: Monday, Dec. 12, 2022: 12:00 noon – 1:00 p.m.
Embargo lift time: Monday, Dec. 12, 2022: 12:00 noon

  • 902: Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort – presenter AnnaLynn Williams, PhD, MS
  • 3663: Formula Feeding Significantly Increases Risk of Iron Deficiency in Very Preterm Infants during the First 4-6 Months of Life – presenter Grace Power 
  • 885: A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease – presenter George Goshua, MD, MSc 

Selected Late-Breaking Abstracts

Moderator: Cynthia Dunbar, MD
Briefing time: Monday, Dec. 12, 2022: 8:30a.m. – 9:30 a.m.
Embargo lift time: Tuesday, Dec. 13, 2022: 9:00a.m.

  • LBA-1: Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial – presenter Mark R. Litzow, MD
  • LBA-2: Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study – presenter Regis Peffault de Latour, MD, PhD
  • LBA-5: Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial – presenter Saskia Middeldorp, MD
  • LBA-6: Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study – presenter Jennifer R. Brown